Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Other Non-Current Liabilities (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Other Non-Current Liabilities for 7 consecutive years, with $3.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Liabilities fell 45.0% to $3.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.2 million, a 45.0% decrease, with the full-year FY2024 number at $7000.0, down 85.71% from a year prior.
  • Other Non-Current Liabilities was $3.2 million for Q3 2025 at Gyre Therapeutics, up from $1.4 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $13.3 million in Q1 2024 to a low of $7000.0 in Q4 2024.
  • A 4-year average of $4.1 million and a median of $3.2 million in 2025 define the central range for Other Non-Current Liabilities.
  • Biggest YoY gain for Other Non-Current Liabilities was 39.55% in 2024; the steepest drop was 85.71% in 2024.
  • Gyre Therapeutics' Other Non-Current Liabilities stood at $55000.0 in 2022, then fell by 10.91% to $49000.0 in 2023, then plummeted by 85.71% to $7000.0 in 2024, then soared by 45957.14% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Other Non-Current Liabilities are $3.2 million (Q3 2025), $1.4 million (Q2 2025), and $3.4 million (Q1 2025).